Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Comparing therapeutic benefit and risk.

R H Meyboom1, A C Egberts

  • 1Netherlands Pharmacovigilance Foundation LAREB, s-Hertogenbosch, The Netherlands.

Therapie
|April 27, 1999
PubMed
Summary

Quantifying drug merit using quality-adjusted life years requires comprehensive data, which is often incomplete. Continuous data collection and overcoming obstacles are crucial for accurate drug benefit-risk assessment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Idiosyncratic reactions to valproate. Clinical risk patterns and mechanisms of toxicity.

The International journal of risk & safety in medicine·2013
Same author

The case for good pharmacovigilance practice.

Pharmacoepidemiology and drug safety·2008
Same author

The spectrum and types of adverse side effects to biological immune modulators: a proposal for new classification.

Folia biologica·2007
Same author

QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine.

The American journal of psychiatry·2006
Same author

Reasons for switching between antipsychotics in daily clinical practice.

Pharmacopsychiatry·2005
Same author

Bladder dysfunction during the use of tramadol.

Pharmacoepidemiology and drug safety·2004

Area of Science:

  • Pharmacoeconomics
  • Drug Safety Evaluation
  • Health Outcomes Research

Background:

  • Drug merit is theoretically quantifiable by calculating benefit and risks using quality-adjusted life years.
  • Current data for most drugs are incomplete, hindering accurate merit assessment.
  • Drug safety is dynamic, and drug merit is context-dependent, not absolute.

Purpose of the Study:

  • To explore quantitative methods for determining drug merit.
  • To identify challenges and potential solutions for comprehensive drug data collection.
  • To evaluate the utility of the 'Principle of Threes' in drug categorization and comparison.

Main Methods:

  • Theoretical exploration of benefit-risk calculation using quality-adjusted life years.
  • Discussion of obstacles to large-scale, continuous data collection in medical practice.
  • Evaluation of preliminary evidence for the 'Principle of Threes'.

Main Results:

  • Comprehensive data are essential for accurate drug merit calculation, but are often lacking.
  • Overcoming scientific, ethical, logistical, and financial obstacles is necessary for routine data collection.
  • The 'Principle of Threes' shows promise for drug categorization and comparison within therapeutic classes.

Conclusions:

  • Quantitative drug merit assessment requires robust, continuous data collection and overcoming practical barriers.
  • The 'Principle of Threes' may aid in drug evaluation, but its broader applicability requires further study.
  • Merit assessment is a valuable tool but will not replace individual therapeutic decision-making.

Related Experiment Videos